Paul Hudson

After Hudson’s removal, media estimates put the combined potential value of pay and share entitlements at nearly €25 million. That estimate must not be presented as cash immediately received: the components have different terms and vesting schedules. Sanofi announced 2025 annual variable pay of €2.616 million, subject to applicable approval rules.

State of the evidence

Sanofi’s compensation disclosures and an APMnews report.

Legal status — source text

Pay controversy with no personal judicial sanction identified.

Attribution

Disputed executive departure compensation and share entitlements.

Under Hudson, Sanofi sold a 50% controlling interest in Opella, maker of Doliprane, to US private equity group CD&R. The plan raised concerns about jobs, French production and medicine supply sovereignty. The French state negotiated industrial guarantees and a small Bpifrance stake before closing in April 2025.

State of the evidence

French government and Sanofi releases, and media reporting.

Legal status — source text

Transaction completed; political and labour controversy without a personal court judgment against Hudson.

Attribution

Strategic decision to sell control of Opella.

Hudson said the US should receive large advance orders of a possible Sanofi COVID-19 vaccine because it had helped fund development. The remarks prompted criticism in France and debate over equitable access. Sanofi’s chairman later said no country would receive special preference.

State of the evidence

Reuters documented the remarks, reaction and clarifications.

Legal status — source text

Public dispute with no personal legal proceedings identified.

Attribution

Communication suggesting possible preferential US access to vaccines.